Background: Long-limb Roux-en-Y (LLRY) reconstruction has recently been implemented as an oncometabolic surgery to improve glycemic control following surgery for gastric cancer (GC); however, data on its feasibility are insufficient. We investigated the 1-year outcomes of LLRY reconstruction for glycemic control in patients with type 2 diabetes (T2D). Methods: We reviewed the records of 15 patients with GC and T2D who underwent LLRY reconstruction after gastrectomy, with biliopancreatic and Roux limb lengths of 130–250 cm, to improve postoperative glycemic control. The primary outcome was the T2D remission (glycated hemoglobin <6.5% without antidiabetic medication) rate at 12 months postoperatively. The diabetes prediction (DP) score and Korean nationwide average T2D remission rates following GC surgery were compared. Results: The mean patient age was 66.5 years (standard deviation [SD] 9.6), mean body mass index was 26.4 kg/m2 (SD 4.4), and mean glycated hemoglobin level was 7.7% (SD 1.5). The overall T2D remission rate was 46.7%. The postoperative T2D remission rate was 12.9% higher than the DP score estimate (33.8%) and 25.7% higher than the Korean national average rate (21%) of T2D remission following GC surgery. Conclusion: Our results show that LLRY reconstruction after gastrectomy is an effective oncometabolic surgery for treating T2D and GC.

Introduction: While the resection of colorectal liver metastases is a well-established procedure, with survival rates superior to chemotherapy alone, controversial data still exist on liver resection for non-colorectal liver metastases (NCRLM). These patients comprise a diverse and heterogeneous group usually excluded from surgery. To date, only few retrospective reports are available on the surgical treatment of NCRLM. The NONCOLMET study aimed to build a comprehensive registry of patients undergoing liver resection for NCRLM, providing robust retrospective and prospective data to describe clinical practices, outcomes, and identify prognostic factors. Methods: The study consists of two phases: (1) retrospective collection of data from patients treated between 2010 and 2024 and (2) prospective enrolment from 2025. Patients aged ≥18 years with histologically confirmed NCRLM undergoing liver resection will be included. Data will be recorded via a standardized electronic case report form on the RedCap platform. The following endpoints will be evaluated: oncological outcomes including overall survival, disease-free survival, and disease relapse; post-operative mortality at 30 and 90 days with causes of death; post-procedural complications; predictor variables of short- and long-term outcomes. These outcomes will be used to elaborate a risk score model. Conclusions: NONCOLMET will offer crucial insights into the surgical management of NCRLM, helping refine patient selection criteria and informing future clinical guidelines.

Introduction: As the nonoperative management of acute appendicitis becomes more widespread, identifying patients at high risk of appendiceal tumors is increasingly important. This study aimed to clarify the predictive factors of appendiceal tumors before appendectomy. Methods: We retrospectively analyzed 434 patients diagnosed with acute appendicitis who underwent emergency or interval appendectomy. Results: Appendiceal neoplasms were found in 3.9% of patients. Patients with tumors were significantly older (64.4 vs. 49.6 years, p < 0.001). The tumor group exhibited a lower appendicolith incidence (48% vs. 12%, p = 0.011) and larger appendiceal diameters (18.0 vs. 12.3 mm, p < 0.001). Multivariate analysis demonstrated that age ≥60 years, absence of appendicolith, and an appendiceal diameter ≥12 mm were independent risk factors of appendiceal tumors. Among patients who underwent interval appendectomy, only the non-tumor group exhibited significant improvement in appendiceal diameter after nonoperative management (tumor, +1.6 mm vs. no tumor, −3.5 mm, p < 0.001). Conclusions: Advanced age, absence of appendicolith, and an enlarged appendiceal diameter may be significant predictive factors of appendiceal tumors. These factors will aid in the selection of appropriate appendicitis treatment strategies.

Introduction: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and lacks local treatment options. This study aimed to assess the feasibility and safety of the first-in-human intraoperative ultrasound-guided intratumoral injection of radioactive holmium-166 microsphere in patients with PDAC. Methods: Patients with proven PDAC eligible for open surgical resection were included. If resection was abandoned during exploration, study intervention was performed. Feasibility was defined by injection success and on-/off-target radiation. Safety was based on adverse event (AE) monitoring for 12 weeks categorized by severity grade and study attribution. Results: Three of the thirteen included patients received study intervention. Injection was successful in all 3 patients. Mean tumor doses of 5.0, 17.0, and 39.0 Gy and maximum tumor doses of 25.0, 41.0 and 256.0 Gy were achieved. Off-target radiation was found once in the lungs and once in the colon with a mean dose <1.0 Gy. There were no AEs with high study attribution, 16, 14, and 19 AEs with low study attribution, including 3, 2, and 4 AEs with grade ≥3. Holmium-166 microspheres appeared hyperdense on CT. Conclusion: Intratumoral injection of holmium-166 microspheres in patients with unresectable PDAC seems feasible and safe. Research into minimally invasive image-guided application is advised.

Introduction: Evidence regarding staging laparoscopy (SL) for clinical metastatic (cM+) gastric cancer (GC) patients is limited. Recently, an Italian Gastric Cancer Research Group (GIRCG) study showed SL changed peritoneal status in over 20% of cases. This study aimed to evaluate SL’s role in cM+ patients and refine its indications. Methods: Clinical data of cM+ GC patients who underwent SL between 2010 and 2022 at nine GIRCG centers were retrospectively analyzed. The primary outcome was SL’s yield, defined as peritoneal status changed by SL over all SLs. Results: Among 182 cM+ patients who received SL, 38 (20.9%) had SL-findings changing peritoneal status. Notably, 10.1% of cases with preoperative signs of carcinomatosis had no peritoneal disease, while 46.3% with extraperitoneal disease alone had peritoneal carcinomatosis (PC) at SL. Thirty-one patients (17.0%) underwent R0 resection: 17 (54.8%) with PC, 3 (9.7%) with liver metastases, 4 (12.9%) with PC and nodal metastases, 2 (6.4%) with lung, and 1 (3.2%) with bone metastases. Seventeen patients with suspected preoperative PC underwent curative treatment: 9 had peritoneal disease ruled out by SL, while the other 8 had limited PC, allowing R0 resection. Logistic regression revealed an inverse correlation between diffuse histotype and absence of PC at SL in patients with peritoneal involvement at imaging (p = 0.02). Conclusion: SL aids in directing cM+ GC patients to appropriate treatment, with a 20.9% yield. For those with peritoneal involvement at imaging, SL helps identify candidates for curative treatment. In patients with extraperitoneal disease, SL should be considered to assess potential radical strategies.

Introduction: The safety and feasibility of robotic pancreatoduodenectomy (RPD) in high-risk patients for postoperative pancreatic fistula (POPF) have rarely been investigated, although the rate of POPF is lower than in open pancreatoduodenectomy (OPD). This study aimed to examine the impact of robotic surgery on POPF in high-risk patients after pancreatoduodenectomy (PD). Methods: We performed a retrospective study of 204 patients who underwent RPD and OPD between January 2018 and June 2023. Of the 204 patients, 126 with high-risk pancreaticojejunostomies for developing POPF were included. The outcomes of RPD and OPD were compared. Multivariate analyses were conducted to identify risk factors associated with the development of clinically relevant POPF (CR-POPF) after surgery. Results: Of the 126 patients, 50 underwent RPD and 76 underwent OPD. The incidence of CR-POPF was significantly lower in the RPD group than in the OPD group (6.0% vs. 38.2%, p < 0.001). Multivariate analyses identified OPD as an independent risk factor associated with CR-POPF (odds ratio [OR]: 7.87, 95% confidence interval [CI]: 2.11–29.4, p = 0.002). Conclusion: This study demonstrated the impact of robotic surgery on POPF in high-risk patients after PD. These results suggest that RPD may be significantly associated with a decreased incidence of CR-POPF in high-risk anastomoses.